NCT06810310招募中2 期
Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Brain measure of GO domain
研究概览
简要总结
The goal of this study is to test addiction-related brain circuitry (motivation/reward and inhibition) as well as neurocognitive circuitry prior to and following low or high dose psilocybin (PEX010 from Filament). Using fMRI, brain circuits will be examined that are relevant to drug relapse as well as neurocognitive flexibility circuits in individuals with opioid use disorder.
Investigators will randomize 24 males and females, aged 18 - 60, in the greater Philadelphia area, to either 1mg or 25 mg of psilocybin. Participants will come to our offices for screening visits - these are assessments, interviews, and some medical tests (such as a history and physical, as well as a fasting blood draw) to help determine eligibility for our study. If eligible, participants will be brought to research offices at 3535 Market Street in Philadelphia for about 7 visits. These visits include pre-dose psilocybin preparation therapy, baseline assessments and neuropsychological testing, psilocybin dosing, post dose therapy visits, and post dose assessments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •An informed consent document voluntarily signed and dated by the subject.
- •Either 1) have a confirmed prescription for BUP-NX in a drug monitoring program database, have been on a stable dose of BUP-NX for at least one week, and plan to continue taking BUP-NX for at least 12 weeks or 2) have received an injection of Sublocade® within the past month, or 3) are currently on methadone maintenance therapy and on a consistent dose for at least a week. Subject must provide a urine that is buprenorphine-positive (for subjects taking buprenorphine) or methadone-positive (for subjects taking methadone), during screening.
- •Physically healthy males and females, aged 18-60 years old, who meet criteria for opioid use disorder (based on DSM-5 criteria) as their primary diagnosis and are voluntarily seeking treatment.
- •Females must be non-pregnant and non-lactating. Additionally, for females with childbearing potential (i.e., have not undergone sterilization via hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, or at least 1 year post-menopausal) participants must agree to use an acceptable form of contraception (e.g. abstinence, intrauterine device, hormonal injection, hormonal implant, hormonal patch/ring/pill, condoms (male or female), etc.) during study participation and to continue its use for the duration of the study
- •Subject must read at or above eighth grade level and speak, understand, and write in English.
- •IQ score of greater than or equal to 80.
排除标准
- •Participation in clinical trial and receipt of investigational drug(s) during 30 days prior to the research study, except as explicitly approved by the Principal Investigator.
- •Currently meets DSM-5 criteria for moderate to severe substance use disorder for any substance other than cocaine, alcohol, marijuana or nicotine as determined by the semi-structured interview. Any prior use of psilocybin is exclusionary. Patients with comorbid Alcohol Use Disorder will be accepted if their alcohol use disorder is not severe enough to require a medicated alcohol detoxification.
- •Meets current or lifetime DSM-5 criteria for schizophrenia or any psychotic disorder, or organic mental disorder or has a first-degree family history of these disorders, this includes a history of hallucinogen-persistent perception disorder (HPPD)
- •Meets current DSM-5 criteria for bipolar disorder
- •-Meets current DSM-5 criteria for severe Major Depressive Disorder (mild and moderate MDD as well as in stable remission are allowed if no suicidal risk and no ongoing antidepressant therapy).
- •Current or past significant trauma exposure with elevated Post-Traumatic Stress symptoms at the discretion of the PI.
- •Presence of any another psychiatric disorder that in the opinion of the PI will interfere with completion of the study or place the patient at heightened risk through participation in the study.
- •Current or past month active suicidal ideations or lifetime history of serious suicidal attempt.
- •Has evidence of significant hepatocellular injury as evidenced by elevated bilirubin levels (greater than 1.3), or, pulmonary (e.g., COPD), endocrine, cardiovascular, renal (creatinine clearance less than or equal to 60ml/min) or gastrointestinal disease (e.g., Crohn's disease), or current HIV infection, and/or clinically significant levels (over 3.5x upper limit of normal) of aspartate aminotransferase (AST), and serumalanine aminotransferase (ALT). Patients with documented Gilbert's syndrome will be included regardless of bilirubin levels.
- •History of serious head trauma or injury causing loss of consciousness that lasted more than 3 minutes and/or associated with skull fracture or intracranial bleeding or abnormal MRI.
- •Seizure disorder or history of seizures not related to drug or alcohol withdrawal (excluding childhood febrile seizure).
- •Presence of magnetically active prosthetics, plates, pins, broken needles, permanent retainer, bullets, etc. in patient's body (unless a radiologist confirms that its presence is unproblematic). An x-ray may be obtained to determine eligibility.
- •Claustrophobia or other medical condition that disables the participant from lying in the MRI for approximately 60 minutes.
- •Non-removable skin patches, at discretion of PI.
- •Has received medication that could interact adversely with psilocybin within the time of administration of study agent based on the Medical Director's guidance.
- •Needs treatment with any psychoactive (e.g., anti-depressants) medications (with the exception of Benadryl used sparingly, if necessary, for sleep).
- •*Have the following cardiovascular conditions:
- •coronary artery disease, congenital long QT syndrome (prior diagnosis), cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction (prior diagnosis);
- •tachycardia (defined as heart rate greater than 100 beats per minute);
- •a clinically significant Screening ECG abnormality (e.g., atrial fibrillation); Note: A QTcF interval greater than 450 milliseconds is considered a clinically significant ECG abnormality
- •artificial heart valve;
- •any other significant current or history of cardiovascular condition, based on the clinical judgment of Medical Director, that would make a participant unsuitable for the study.
- •*At Screening or Baseline have elevated blood pressure as defined as:
- •Screening blood pressure SBP greater than135 mmHg or DBP greater than 85 mmHg on three separate readings; or
- •Baseline blood pressure SBP greater than140 mmHg or DBP greater than 90 mmHg on three separate readings
研究组 & 干预措施
High dose psilocybin
Experimental
25 mg PEX010 capsule, single dose
干预措施: Psilocybin (high dose) (Drug)
Low dose psilobyin
Active Comparator
1 mg PEX010 capsule, single dose
干预措施: psilocybin (low dose) (Drug)
结局指标
主要结局
Brain measure of GO domain
时间窗: One week pre dose and one week post dose
Using fMRI, Investigators will measure the brain response to 500ms evocative cues and 6 second drug-related videos that trigger drug desire
Behavioral measure of GO domain
时间窗: One week pre dose and one week post dose
Using a the Affect Bias behavioral task, Investigators will measure the affective bias to opioid and other evocative visual cues.
次要结局
- Brain measure of STOP domain(weeks 1 through 8 (outcomes phase))
- Behavioral measure of STOP domain(One week pre dose and one week post dose)
研究者
Anna Rose Childress, Ph.D.
Research Associate Professor, Department of Psychiatry
University of Pennsylvania
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Randomized Neuroimaging Trial of Psilocybin in DepressionDepressive DisorderMajor Depressive DisorderNCT06072898Sunnybrook Health Sciences Centre50
已完成
不适用
Brain Function in Response to Motivational StimuliDrug DependenceNCT00047866National Institute on Alcohol Abuse and Alcoholism (NIAAA)38
招募中
2 期
Psilocybin-Assisted Psychotherapy for Alcohol Use DisorderAlcoholismAlcohol Use DisorderNCT05995769University of Calgary128
已完成
1 期
Psilocybin-assisted Therapy for Phantom Limb PainPhantom Limb PainNCT05224336University of California, San Diego10
招募中
2 期
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUDAlcohol Use DisorderNCT06349083NYU Langone Health200